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Radioimmunotherapy of mice bearing breast tumors with
177
Lu-labeled trastuzumab
Samira RASANEH1, Hossein RAJABI2, Shahram AKHLAGHPOOR3, Shahab SHEYBANI1

Aim: In the present study, we investigated the therapeutic efficacy of trastuzumab labeled with lutetium-177 (177Lu) in
mice bearing breast tumors.
Materials and methods: Trastuzumab was labeled with 177Lu via DOTA as a chelator. In vitro and in vivo quality control
tests of incorporated activity, immunoreactivity, stability of 177Lu–trastuzumab, biodistribution, and imaging studies
were performed. Therapeutic efficacy and dosimetry studies were carried out in mice with breast tumors.
Results: The good in vitro and in vivo quality control results suggested that 177Lu–trastuzumab could be used as a
radioimmunotherapy agent. Reductions of 81% and 98% in the mean tumor volume for the group that received 177Lu–
trastuzumab [7.4 MBq] were observed at 42 and 45 days after treatment, respectively.
Conclusion: The results showed that 177Lu–trastuzumab could be considered as a possible new radiopharmaceutical
agent for use in radioimmunotherapy of breast cancer in humans.
Key words: Radioimmunotherapy, breast cancer, lutetium-177, trastuzumab, gamma camera imaging

Introduction
The development of antibodies for cancer therapy
has emerged as one of the most promising areas in
oncology. Trastuzumab (trade name: Herceptin) is
a humanized IgG1 monoclonal antibody directed
against the extracellular domain of the human
epidermal growth factor receptor 2 (HER2) (1).
This receptor is overexpressed in several epithelial
tumors, including 35%–45% of all pancreatic
adenocarcinomas, 25%–30% of ovarian cancers, and
4%–83% of colorectal adenocarcinomas (2–4).
HER2 is overexpressed in 20%–30% of early-stage
breast cancers. Patients with HER2-overexpressing
breast cancer may be candidates for trastuzumab
treatment (5). However, due to the cardiotoxicity
of trastuzumab, some patients cannot tolerate the

treatment due to preexisting heart conditions (6).
Trastuzumab is an expensive antibody and the cost of
cancer therapy is very high (7).
Radioimmunotherapy (RIT) is a targeted
treatment that has the potential to augment the
efficacy of conventional monoclonal antibodies (8).
In RIT, a radioisotope is coupled to a monoclonal
antibody to form a tumor-specific target agent (9).
We demonstrated that trastuzumab can be an
effective carrier of RIT because it requires a smaller
amount of antibody and therefore can reduce both
side effects and cost (10–12).
In this study, the therapeutic efficacy of 177Lu–
trastuzumab was investigated in mice with breast
tumors.
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Materials and methods
Materials
Trastuzumab (Herceptin) was purchased as a 150mg vial from Genentech (San Francisco, USA). The
177
LuCl3 was produced by bombarding 176Lu2O3 (74%;
Campro Scientific, Berlin, Germany) dissolved in
0.05 M HCl at a flux of 2.6 × 1014 n cm–2 s–1 for 10
days. All chemical reagents used in this study were
prepared with deionized (DI) water. To prepare a 10×
conjugation carbonate buffer, NaHCO3 (40.22 g),
Na2CO3 (2.25 g), and NaCl (87.66 g) were dissolved
in 1000 mL of DI water.
Radiolabeling of trastuzumab with 177Lu
Trastuzumab was conjugated to DOTA as previously
described (11,12). Briefly, trastuzumab (5 mg, 2 mL)
in carbonate buffer (pH 8.6) was slowly added to
NHS-DOTA (1 mg, 2.5 mL) and gently mixed for
24 h at room temperature. After purification, the
number of chelates per antibody was determined
using a spectrometric assay based on the titration
of the Cu(II)–Arsenazo(III) complex (13). The final
protein concentration was determined by the Lowry
method (14).
For radiolabeling, 5 mCi of 177LuCl3 with a typical
specific activity of 20 Ci mg–1 was added to the
trastuzumab–DOTA conjugation (150 µg) and
heated for 3 h at 37 °C.
Quality control of the trastuzumab–DOTA–177Lu
complex
The number of chelates per antibody and the
incorporated activity of 177Lu was determined as
described previously (10). The stability of the complex
in human blood serum was analyzed by instant
thin layer chromatography. The immunoreactivity
was also tested in SKBr3 cells based on the method
described by Lindmo et al. (15).
Biodistribution and imaging study of the complex
in mice bearing tumors
Breast tumors were established by subcutaneous
injection of murine mammary carcinoma cells
(approximately 1012 cells) in the right flank region
of inbred female BALB/c mice (20–25 g, 8–10 weeks
old). The tissue distribution experiments were
performed when the tumor volumes reached 40–60
mm3. The effect of trastuzumab on tumor cells was

assessed by immunohistochemistry using the rabbit
antimouse peroxidase technique (16).
The mice (n = 35) were injected intravenously with
Lu–trastuzumab (7.4 MBq 0.1 mL–1, approximately
30 µg trastuzumab) via the tail veins. At 1, 2, 3, 4, 5, 6,
and 7 days after the injection, groups of 5 animals were
killed and tissues were removed, checked for 177Lu
activity, and compared with the percentage of injected
dose per gram of tissues (ID% g–1). The biodistribution
of 177Lu–IgG was studied at 1 and 7 days after injection.
Before being killed, the animals were anesthetized by a
combination of xylazine hydrochloride and ketamine
hydrochloride. Scintigraphic images (550,000 counts,
256 × 256 matrix) were recorded using a gamma
camera (e.cam, Siemens Medical Systems, Erlangen,
Germany) equipped with a low-energy, highresolution collimator.
177

Radioimmunotherapy and tumor response
RIT was performed in the mice with murine breast
tumors. Mice were randomly divided into 5 groups
each containing 10 mice. Group 1 was injected with
7.4 MBq of 177Lu–trastuzumab (30 µg trastuzumab,
0.1 mL), group 2 with 5.5 MBq of 177Lu–trastuzumab
(25 µg trastuzumab, 0.1 mL), group 3 with 7.4 MBq
of 177Lu (unspecific control), group 4 with unlabeled
trastuzumab (30 µg trastuzumab, 0.1 mL), and group
5 with phosphate buffer saline (PBS). The sizes of
the tumors were measured in 3 dimensions every 3
days with an electronic slide caliper until the tumor
volumes exceeded 2000 mm3 (50–100 days). Tumor
volume was calculated as:
o = 4 r # r1 # r2 # r3 ,
3
where r1, r2, and r3 are tumor radii in 3 dimensions,
expressed in cubic millimeters. Tumor inhibition rate
(TIR) was calculated as follows:
TIR (%) = o1 –o2 # 100,
o1
where ν1 is the average volume of the tumors in the
PBS group and ν2 is the average volume of the tumors
in the treatment group. The doubling and quintupling
times of the tumors were calculated and compared in
groups.
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The percentage of weight loss in mice was
considered as complex toxicity. The body weight was
expressed as relative body weight compared with
the body weight on the first day of treatment, and
toxicity was deﬁned as a 15% body weight loss in
any animal. When the tumor volume exceeded 2000
mm3, the mice were killed for humane reasons. All
animal experiments were performed in compliance
with the regulations of our institution and according
to accepted guidelines governing such work.
Dosimetry
The estimated radiation dose delivered to the
tumor and normal organs was calculated from
the biodistribution data. Brieﬂy, the trapezoidal
regions were deﬁned by the time–activity data
after correction for physical decay. The resulting
integral was converted to Gy MBq–1 using S values
(MIRDOSE3; unit density sphere model) calculated
for each isotope by assuming uniformly distributed
activity in small unit-density spheres, which do not
assume 100% absorption of β-particles (17–19).
For better comparison, the organ doses were
estimated by the Monte Carlo technique as
well. Briefly, the Moby phantom was used as a
mathematical mouse model (20). A spherical tumor
shape (approximately 2000 mm3) was inserted into
the right flank of mouse phantom.
The organ activity of the phantom was adjusted
according to the calculated cumulated activities. The
GATE Monte Carlo package (version 4.0.0) was used
for dose calculation (Gy MBq–1) in the organs of the
mouse phantom (21).

Statistical analysis
SPSS (version 13.0, SPSS Inc.) was used for statistical
analyses. For all of the tests, P < 0.05 was considered
as statistically significant. The t-test was used to
analyze the biodistribution data and differences in
the growth of the tumors.
Results
The number of chelates per antibody (5.5–6),
incorporated activity (81%), and immunoreactivity
(87%) were optimal for the 177Lu–DOTA–
trastuzumab. On average, 86% and 81% of the
complex was stable in the phosphate buffer and in
human blood serum for up to 4 days, respectively.
The results are shown in Figure 1.
Biodistribution and imaging study of the complex
in mice bearing tumors
The immunohistochemistry results revealed that the
murine breast tumor used in this study expressed
moderate levels of HER2. The tissue distribution
experiments were performed in mice with breast
tumors at 1–7 days after administration of 177Lu–
trastuzumab and the results are presented in Table 1.
In all organs, the activity of 177Lu decreased with time,
excluding the tumor, which continued to accumulate
radioactivity for up to 2 days after the injection. The
maximum tumor uptake was 21.24 ± 2.6 ID% g–1 at 2
days and then decreased gradually to 18.21 ± 5.9 ID%
g–1 at 7 days. The percentage of ID g–1 for all normal
organs was always less than 8%.
100

A
y = 1E+06x + 1.118
R² = 0.997

5
4
3
2

80
70
60

1
0

buffer

90

6

Percent stability

Total binding activity

7

serum

B

0

5E-09

1E-09 1.5E-08

2E-08 2.5E-08 3E-08 3.5E-08

Number of cells

50

0.25

1

2
Time (days)

3

4

Figure 1. A) Immunoreactivity and B) stability in the phosphate buffer and in human blood serum for up to 4 days of 177Lu–trastuzumab.
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Table 1. Tumor-to-organ ratios for 177Lu–trastuzumab in mice with breast tumors.
Tissue

24 h

48 h

96 h

120 h

168 h

Blood

2.27 ± 0.54

5.15 ± 0.08

10.52 ± 0.07

17.28 ± 0.10

23.09 ± 0.09

Liver

2.82 ± 0.97

4.88 ± 0.52

9.65 ± 1.04

15.45 ± 1.28

19.59 ± 1.57

Spleen

4.03 ± 1.03

6.78 ± 1.0

10.42 ± 1.09

17.11 ± 1.43

20.79 ± 0.97

Kidney

3.47 ± 0.97

4.22 ± 1.11

8.29 ± 1.08

15.91 ± 0.99

21.81 ± 1.96

Bone

5.78 ± 0.97

4.26 ± 1.52

9.67 ± 1.08

13.9 ± 0.88

18.26 ± 0.97

Stomach

16.17 ± 2.61

20.99 ± 3.53

24.35 ± 4.10

26.88 ± 4.98

37.83 ± 5.17

Intestine

11.16 ± 2.34

17.49 ± 2.68

22.74 ± 3.74

28.92 ± 3.39

32.51 ± 5.20

Colon

11.21 ± 2.10

18.15 ± 2.06

22.32 ± 3.39

26.56 ± 3.54

24.48 ± 2.81

Muscle

15.81 ± 1.88

21.74 ± 1.95

23.63 ± 2.63

23.55 ± 2.49

25.07 ± 2.67

Lung

8.99 ± 1.05

15.41 ± 1.29

19 ± 1.47

23 ± 1.35

28 ± 1.43

Heart

5.62 ± 1.28

9.54 ± 1.56

11.87 ± 1.64

19.83 ± 2.55

25.69 ± 3.12

To demonstrate the specificity of 177Lu-labeled
trastuzumab uptake by tumors, 177Lu-labeled IgG
as a nonspecific antibody was also tested. The
biodistribution studies were performed in mice with
breast tumors on day 1 and day 7 postinjection and
the results are shown in Figure 2. 177Lu–trastuzumab
was accumulated at very high concentrations in
tumors compared with 177Lu–IgG (about 5 times or
more). 177Lu was eliminated from the blood quickly
(on the first day) after administration of 177Lu–IgG
and could be detected only in the liver, kidney, and
bone after 7 days.

The gamma camera images from a representative
mouse at day 1 and day 7 after injection of 177Lu–
trastuzumab are shown in Figure 3. The tumors
are clearly evident in all images. A small amount of
radioactivity was also observed in the liver area on
day 1 postinjection.
Radioimmunotherapy and tumor response
The therapeutic efficacy of 177Lu–trastuzumab (7.4
and 5.5 MBq), trastuzumab (30 µg), 177LuCl3 (7.4
MBq), and PBS (as control) was evaluated in mice
with breast tumors and the results are presented in
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Figure 2. Tissue distributions of 177Lu–IgG (7.4 MBq) in mice
with breast tumors on days 1 and 7.

Figure 3. The gamma camera images acquired on A) day 1 and
B) day 7 after injection of 177Lu–trastuzumab.
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Figure 4. The tumor size significantly increased (P <
0.05) in PBS and native antibody groups compared
with 177Lu–trastuzumab. From day 30, significant (P
< 0.05) differences were observed in tumor growth
between the mice treated with 7.4 MBq and 5.5
MBq of the complex. No group of mice showed any
significant (P > 0.05) weight loss after injection (data
not shown). Reductions of 81% and 98% in the mean
tumor volume for the group that received 177Lu–
trastuzumab (7.4 MBq) were observed at 42 and 45
days postinjection, respectively. The comparison
between doubling and quintupling time of tumors
after administration of 177Lu–trastuzumab (7.4 MBq),

2000

Dosimetry
An estimation of mean tissue-absorbed dose
calculated by MIRDOSE3 (19) and the Monte Carlo
simulation using the Moby mouse phantom (20)
and GATE simulator (21) are shown in Table 2.
Some differences between the calculated dose with
MIRDOSE3 and the Monte Carlo simulation were
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Figure 4. Comparison of the mean tumor volume in treatment
groups. Each group is shown as a function of time and
consists of 10 mice. The mice were killed when the
tumor size exceeded 2000 mm3.
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Lu–trastuzumab (5.5 MBq), trastuzumab, 177Lu (7.4
MBq), and PBS is shown in Figure 5. The doubling
time for the group that received 177Lu–trastuzumab
(7.4 MBq) was 45 days, whereas this time for the PBS
group was 4.5 days.

177

Figure 5. Comparison between doubling and quintupling time of
tumors after administration of 177Lu–trastuzumab (7.4
MBq), 177Lu–trastuzumab (5.5 MBq), trastuzumab,
177
Lu (7.4 MBq), and PBS.

Table 2. A comparison between MIRDOSE3 and GATE simulators in the calculation of
mean absorbed doses to the mice tissues treated with 7.4 MBq of the complex.
Absorbed dose to different organs
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MIRDOSE3

GATE simulator

Tissue

Gy MBq–1

Gy MBq–1

Tumor

6.35 ± 1.2

8.3

Liver

0.98 ± 0.3

1.49

Spleen

0.7 ± 0.1

1.4

Kidney

0.54 ± 0.09

0.49

Blood

1.62 ± 0.13

3.54

Colon

0.19 ± 0.03

0.14

Bone

0.41 ± 0.09

0.38
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seen. This may be due to the fact that the organ mass
of the Moby phantom at the standard settings differed
from the experimental mice, but in general the mean
absorbed dose with both methods was similar. The
mean absorbed dose to tumor and select organs was
recorded as gray per megabecquerel.
Discussion
Radiolabeled monoclonal antibodies have shown great
promise for cancer therapy (22–26). Trastuzumab is a
monoclonal antibody specific for the HER2 receptor
and is approved for the treatment of metastatic breast
cancer (27). HER2 is overexpressed in a variety of
epithelial cancers and is being used as an ideal target
in RIT research (2–4). Many radioisotopes are of
potential use in RIT (22–26).
We selected 177Lu for trastuzumab labeling due to
its promising physical and chemical characteristics.
177
Lu displays low-energy β-emission (0.497 MeV,
78.7%) with minimal tissue penetration (0.04–
1.8 mm), making it suitable for the therapy of
small and metastatic tumors (28–31). The halflife (6.65 days) of 177Lu allows the application of
sophisticated procedures to synthesize and purify
the radiopharmaceutical. 177Lu also emits γ-photons
(208 keV, 11% abundance) suitable for imaging with
a conventional gamma camera, which may be used
to image the distribution of radiopharmaceuticals
in the patient’s body. This technique is potentially
very important for the determination of the dose
delivered to tumors and normal tissues in patients.
The other advantage of 177Lu is the possibility for its
production in reactors at a large scale at a low price
and high specific activity.
In previous studies we labeled trastuzumab with
Lu by different methods, found the best labeling
condition, and investigated its cytotoxicity in SKBr3
and MCF7 breast cancer cell lines (10–12).
177

In the present study, the therapeutic efficacy of
Lu–trastuzumab was assessed in mice with breast
tumors. The biodistribution study showed that
177
Lu–trastuzumab accumulated to a greater extent
in tumors than in all other analyzed organs (less
than 10%). After 2 days, the tumor uptake of 177Lu–
trastuzumab was 24.14 ± 3.6 ID% g–1; in contrast, the
value reported for 188Re-SOCTA–trastuzumab was
7.23 ± 1.12 ID% g–1 (22).
177

The main objective of RIT is the treatment of
small metastases. Thus, in this experiment, 177Lu–
trastuzumab was injected into the mice 10 days after
tumor implantation, when the mean sizes of the
tumors were 40–60 mm3. The mice that received 7.4
and 5.5 MBq of 177Lu–trastuzumab had significantly
(P < 0.05) delayed tumor progression compared with
native trastuzumab and control groups. The absorbed
doses from 177Lu–trastuzumab to tumor and liver
were 6.35 ± 1.2 Gy MBq–1 and 0.98 ± 0.3 Gy MBq–1,
respectively. In treatment with 90Y–trastuzumab,
the absorbed dose to tumor was 0.48 Gy MBq–1,
compared to the liver, which received 0.47 Gy MBq–1
(32). We suggest that the treatment efficiency could
be improved further by using higher amounts of
177
Lu–trastuzumab. It is probable that the maximum
tolerable dosage was not reached in this study,
because no adverse effects could be found from the
treatment. Moreover, the spontaneous breast tumor
that we used in this study expressed moderate levels
of HER2. It is probable that 177Lu–trastuzumab may
show better results with tumors that overexpress
HER2, but that needs more investigation.
Lu–DOTA–trastuzumab could be considered
for further evaluation in humans as a new
radiopharmaceutical for use in the RIT of breast
cancer. 177Lu–trastuzumab showed promising
properties as an effective radioimmunoconjugate
for RIT of HER2-overexpressing breast tumors.
This complex can be considered as an alternative to
131
I-labeled antibodies for further investigation.
177
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